Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48228 | 0.79 | DPYD (0.65) | DPYDMAPTALDH1A1GAALMNA | |
| SCHEMBL170251 | 0.77 | DPYD (1.00) | DPYDMAPTALDH1A1GAALMNA | |
| SCHEMBL12903446 | 0.74 | DPYD (0.59) | DPYDMAPTALDH1A1GAALMNA | |
| SCHEMBL190003 | 0.74 | DPYD (0.62) | DPYDMAPTALDH1A1GAALMNA | |
| SCHEMBL1558078 | 0.74 | DPYD (0.59) | DPYDMAPTALDH1A1GAALMNA | |
| SCHEMBL65892 | 0.74 | DPYD (0.62) | DPYDMAPTALDH1A1GAALMNA | |
| SCHEMBL28624115 | 0.72 | DPYD (0.62) | DPYDMAPTALDH1A1GAALMNA | |
| SCHEMBL190329 | 0.71 | DPYD (0.59) | DPYDMAPTALDH1A1GAALMNA | |
| SCHEMBL190328 | 0.71 | DPYD (0.59) | DPYDMAPTALDH1A1GAALMNA | |
| SCHEMBL7606808 | 0.70 | DPYD (0.53) | DPYDMAPTALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | disclosed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | disclosed |
| EP-2462122-A1 | NOVEL VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-06-13 | — | — | EP | disclosed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2011015641-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | DPYD 224/4885MAPT 2788/4885ALDH1A1 3260/4885 |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | DPYD 224/4885MAPT 2788/4885ALDH1A1 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.